The overall response rate of HER2-positive breast cancers to Tz is reported to be 12–34% for a median duration of 9 months; however, Tz is combined with other chemotherapeutic drugs, such as taxane for recurred or metastatic breast cancers, to increase cytotoxic efficacy. The gene discussed is ERBB2; the disease is breast carcinoma.